Deciphera Pharmaceuticals, Inc.’s Phase III vimseltinib has a potentially smooth path to market in tenosynovial giant cell tumor (TGCT) thanks to a safety profile more benign than a competing drug for the condition already on the market. Decipher should also benefit from marketing to physicians that mostly overlaps with the one that Deciphera targets for its drug for gastrointestinal stromal tumors (GIST).
The Waltham, MA-based company announced 30 October positive topline results from the Phase III MOTION study of vimseltinib as well as updated Phase I/II results from a study of the...
Key Takeaways
-
Vimseltinib showed a positive improvement in objective response rate compared with placebo in the Phase III MOTION trial, but no cholestatic hepatotoxicity.
-
The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?